MX2010008835A - Metodo para predecir respuesta al tratamiento farmacologico con chaperona de enfermedades. - Google Patents
Metodo para predecir respuesta al tratamiento farmacologico con chaperona de enfermedades.Info
- Publication number
- MX2010008835A MX2010008835A MX2010008835A MX2010008835A MX2010008835A MX 2010008835 A MX2010008835 A MX 2010008835A MX 2010008835 A MX2010008835 A MX 2010008835A MX 2010008835 A MX2010008835 A MX 2010008835A MX 2010008835 A MX2010008835 A MX 2010008835A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmacological chaperone
- diseases
- predict response
- treatment
- galactosidase
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 108010006519 Molecular Chaperones Proteins 0.000 title abstract 3
- 230000000144 pharmacologic effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000024720 Fabry Disease Diseases 0.000 abstract 2
- 102000002464 Galactosidases Human genes 0.000 abstract 1
- 108010093031 Galactosidases Proteins 0.000 abstract 1
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 1
- 229950007469 migalastat Drugs 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2814108P | 2008-02-12 | 2008-02-12 | |
| US3568408P | 2008-03-11 | 2008-03-11 | |
| US9363108P | 2008-09-02 | 2008-09-02 | |
| US11349608P | 2008-11-11 | 2008-11-11 | |
| PCT/US2009/033963 WO2009102895A2 (en) | 2008-02-12 | 2009-02-12 | Method to predict response to pharmacological chaperone treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010008835A true MX2010008835A (es) | 2010-10-20 |
Family
ID=40957500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010008835A MX2010008835A (es) | 2008-02-12 | 2009-02-12 | Metodo para predecir respuesta al tratamiento farmacologico con chaperona de enfermedades. |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8592362B2 (enExample) |
| EP (4) | EP2252313B1 (enExample) |
| JP (7) | JP5844045B2 (enExample) |
| AU (7) | AU2009214648B2 (enExample) |
| CA (1) | CA2715407C (enExample) |
| CY (3) | CY1116466T1 (enExample) |
| DK (3) | DK3470077T3 (enExample) |
| ES (3) | ES2541933T3 (enExample) |
| HR (3) | HRP20150728T1 (enExample) |
| HU (3) | HUE026543T2 (enExample) |
| LT (2) | LT3470077T (enExample) |
| MX (1) | MX2010008835A (enExample) |
| PL (3) | PL3470077T3 (enExample) |
| PT (3) | PT2946785T (enExample) |
| SI (3) | SI3470077T1 (enExample) |
| WO (1) | WO2009102895A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2652553C (en) | 2006-05-16 | 2020-08-18 | Amicus Therapeutics, Inc. | Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease |
| LT3470077T (lt) | 2008-02-12 | 2021-02-25 | Amicus Therapeutics, Inc. | Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas |
| AU2009223125A1 (en) * | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for Pompe disease |
| AR078498A1 (es) * | 2009-10-01 | 2011-11-09 | Baylor Res Inst | Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry |
| US20120283290A1 (en) * | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| SG10202003753PA (en) | 2014-09-30 | 2020-05-28 | Amicus Therapeutics Inc | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
| AU2016233135B2 (en) | 2015-03-19 | 2021-07-08 | Translate Bio, Inc. | mRNA therapy for pompe disease |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| CA3010205A1 (en) | 2015-12-30 | 2017-07-06 | Amicus Therapeutics, Inc. | Augmented acid alpha-glucosidase for the treatment of pompe disease |
| SMT202100452T1 (it) | 2015-12-30 | 2021-09-14 | Amicus Therapeutics Inc | Alfa-glucosidasi acida potenziata per il trattamento della malattia di pompe |
| KR20190087673A (ko) | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| CN109475607B (zh) | 2016-03-30 | 2022-04-26 | 阿米库斯治疗学公司 | 包含重组酸性α-葡糖苷酶的配制品 |
| KR20250017756A (ko) | 2016-03-30 | 2025-02-04 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| SG11201808592PA (en) * | 2016-03-30 | 2018-10-30 | Amicus Therapeutics Inc | Method for selection of high m6p recombinant proteins |
| EP4378524A3 (en) | 2016-07-19 | 2024-08-14 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naive and ert-experienced patients |
| JP6546135B2 (ja) | 2016-08-24 | 2019-07-17 | 株式会社ノリタケカンパニーリミテド | 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット |
| ES3047063T3 (en) * | 2016-10-20 | 2025-12-03 | Sangamo Therapeutics Inc | Methods and compositions for the treatment of fabry disease |
| EA039750B1 (ru) * | 2017-03-30 | 2022-03-10 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| EP4223310A3 (en) | 2017-05-15 | 2023-10-11 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
| TW202322814A (zh) | 2017-05-30 | 2023-06-16 | 美商阿米庫斯醫療股份有限公司 | 治療有腎損傷的法布里患者的方法 |
| WO2018222655A1 (en) | 2017-05-30 | 2018-12-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| WO2019017938A1 (en) | 2017-07-19 | 2019-01-24 | Amicus Therapeutics, Inc. | TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES |
| JP7755929B2 (ja) | 2017-08-28 | 2025-10-17 | アミカス セラピューティックス インコーポレイテッド | ファブリー病患者における心臓機能の強化及び／または安定化方法 |
| CN112203657A (zh) | 2018-02-06 | 2021-01-08 | 阿米库斯治疗学公司 | 患有经典法布里病的患者的治疗 |
| WO2019157047A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| KR20210046729A (ko) | 2018-08-20 | 2021-04-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
| WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
| TW202042812A (zh) | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
| CA3141226A1 (en) | 2019-06-11 | 2020-12-17 | Franklin Johnson | Methods of treating fabry disease in patients having renal impairment |
| US11833164B2 (en) * | 2019-08-07 | 2023-12-05 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| US20230220320A1 (en) | 2019-09-06 | 2023-07-13 | Amicus Therapeutics, Inc. | Method For Capturing And Purification Of Biologics |
| SI4114390T1 (sl) * | 2020-03-06 | 2025-03-31 | Amicus Therapeutics, Inc. | Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| US20240293387A1 (en) | 2021-07-12 | 2024-09-05 | Amicus Therapeutics, Inc. | Methods of Treating Fabry Disease in Pediatric Patients |
| KR20250007602A (ko) | 2022-05-05 | 2025-01-14 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료에 대한 방법 |
| KR20250110931A (ko) | 2022-12-02 | 2025-07-21 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 소아 환자의 영아-발병 폼페병 치료에 대한 방법 |
| CN121057588A (zh) | 2022-12-02 | 2025-12-02 | 阿米库斯治疗学公司 | 用于在儿科患者中治疗迟发性庞贝病的方法 |
| US20240197706A1 (en) | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21381A (en) * | 1858-08-31 | Bracelet | ||
| US203019A (en) * | 1878-04-30 | Improvement in circuits for acoustic or telephonic telegraphs | ||
| US270486A (en) * | 1883-01-09 | Bundle-separating attachment for self-binding harvesters | ||
| US264467A (en) * | 1882-09-19 | Chables h | ||
| US3586908A (en) | 1969-02-28 | 1971-06-22 | Robert E Vosteen | Automatic potential control system for electrophotography apparatus |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| JP2000509971A (ja) | 1996-04-10 | 2000-08-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 化学的シャペローンを用いる遺伝的欠陥の修正 |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US6244113B1 (en) | 1999-10-29 | 2001-06-12 | University Of Alabama In Huntsville | Method and apparatus for measuring microgravity acceleration |
| US7842470B2 (en) * | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
| JP2008545657A (ja) * | 2005-05-17 | 2008-12-18 | アミカス セラピューティックス インコーポレイテッド | １−デオキシノジリマイシンおよび誘導体を用いるポンペ病の治療方法 |
| KR20080033242A (ko) * | 2005-06-08 | 2008-04-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법 |
| WO2008045015A1 (en) | 2005-06-08 | 2008-04-17 | Amicus Therapeutics, Inc. | Imino and amino sugar purification |
| US7790364B2 (en) * | 2006-01-27 | 2010-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for high throughput screening of pharmacological chaperones |
| CA2652553C (en) | 2006-05-16 | 2020-08-18 | Amicus Therapeutics, Inc. | Use of 1-deoxygalactonojirimycin or a salt thereof in the treatment of fabry disease |
| PL1860101T3 (pl) | 2006-05-24 | 2011-10-31 | Amicus Therapeutics Inc | Sól winianu izofagominy i sposoby zastosowania |
| MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| LT3470077T (lt) | 2008-02-12 | 2021-02-25 | Amicus Therapeutics, Inc. | Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas |
| US8321148B2 (en) | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| ES2585584T3 (es) | 2009-05-26 | 2016-10-06 | Amicus Therapeutics, Inc. | Utilización de chaperonas farmacológicas para mejorar la fabricación y la purificación de ß-glucosidasa ácida |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| JP5739898B2 (ja) | 2009-11-17 | 2015-06-24 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３） |
| CN103974619B (zh) | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| EP2874648A4 (en) | 2012-07-17 | 2015-12-30 | Amicus Therapeutics Inc | CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| KR20190087673A (ko) | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| EP4378524A3 (en) | 2016-07-19 | 2024-08-14 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naive and ert-experienced patients |
| JP2020503900A (ja) | 2017-01-10 | 2020-02-06 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ |
| WO2018222655A1 (en) | 2017-05-30 | 2018-12-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| WO2019017938A1 (en) | 2017-07-19 | 2019-01-24 | Amicus Therapeutics, Inc. | TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES |
| JP7755929B2 (ja) | 2017-08-28 | 2025-10-17 | アミカス セラピューティックス インコーポレイテッド | ファブリー病患者における心臓機能の強化及び／または安定化方法 |
| CN112203657A (zh) | 2018-02-06 | 2021-01-08 | 阿米库斯治疗学公司 | 患有经典法布里病的患者的治疗 |
| WO2019157047A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| KR20210046729A (ko) | 2018-08-20 | 2021-04-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| CA3141226A1 (en) | 2019-06-11 | 2020-12-17 | Franklin Johnson | Methods of treating fabry disease in patients having renal impairment |
| US11833164B2 (en) | 2019-08-07 | 2023-12-05 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
-
2009
- 2009-02-12 LT LTEP18201960.4T patent/LT3470077T/lt unknown
- 2009-02-12 DK DK18201960.4T patent/DK3470077T3/da active
- 2009-02-12 LT LTEP15162630.6T patent/LT2946785T/lt unknown
- 2009-02-12 ES ES09710178.6T patent/ES2541933T3/es active Active
- 2009-02-12 HU HUE09710178A patent/HUE026543T2/hu unknown
- 2009-02-12 JP JP2010546901A patent/JP5844045B2/ja active Active
- 2009-02-12 EP EP09710178.6A patent/EP2252313B1/en active Active
- 2009-02-12 WO PCT/US2009/033963 patent/WO2009102895A2/en not_active Ceased
- 2009-02-12 DK DK15162630.6T patent/DK2946785T3/en active
- 2009-02-12 ES ES15162630T patent/ES2716502T3/es active Active
- 2009-02-12 SI SI200932099T patent/SI3470077T1/sl unknown
- 2009-02-12 EP EP15162630.6A patent/EP2946785B1/en active Active
- 2009-02-12 MX MX2010008835A patent/MX2010008835A/es active IP Right Grant
- 2009-02-12 PT PT15162630T patent/PT2946785T/pt unknown
- 2009-02-12 PT PT97101786T patent/PT2252313E/pt unknown
- 2009-02-12 ES ES18201960T patent/ES2836121T3/es active Active
- 2009-02-12 SI SI200931229T patent/SI2252313T1/sl unknown
- 2009-02-12 PL PL18201960T patent/PL3470077T3/pl unknown
- 2009-02-12 HU HUE18201960A patent/HUE051377T2/hu unknown
- 2009-02-12 CA CA2715407A patent/CA2715407C/en active Active
- 2009-02-12 DK DK09710178.6T patent/DK2252313T3/en active
- 2009-02-12 PT PT182019604T patent/PT3470077T/pt unknown
- 2009-02-12 EP EP18201960.4A patent/EP3470077B1/en active Active
- 2009-02-12 HU HUE15162630A patent/HUE042882T2/hu unknown
- 2009-02-12 AU AU2009214648A patent/AU2009214648B2/en active Active
- 2009-02-12 EP EP20192637.5A patent/EP3824900A1/en active Pending
- 2009-02-12 PL PL09710178T patent/PL2252313T3/pl unknown
- 2009-02-12 PL PL15162630T patent/PL2946785T3/pl unknown
- 2009-02-12 HR HRP20150728TT patent/HRP20150728T1/hr unknown
- 2009-02-12 SI SI200931920T patent/SI2946785T1/sl unknown
-
2010
- 2010-08-12 US US12/855,468 patent/US8592362B2/en not_active Ceased
- 2010-08-20 US US12/860,611 patent/US20110152319A1/en not_active Abandoned
-
2013
- 2013-10-15 US US14/054,369 patent/US9095584B2/en active Active
-
2014
- 2014-09-10 AU AU2014221321A patent/AU2014221321B2/en active Active
- 2014-12-02 JP JP2014244283A patent/JP2015091239A/ja active Pending
-
2015
- 2015-06-05 US US14/731,603 patent/US9545397B2/en active Active
- 2015-07-08 CY CY20151100595T patent/CY1116466T1/el unknown
-
2016
- 2016-03-01 JP JP2016039171A patent/JP6672013B2/ja active Active
- 2016-07-20 AU AU2016206297A patent/AU2016206297A1/en not_active Abandoned
- 2016-09-19 US US15/268,662 patent/US20170003301A1/en not_active Abandoned
-
2017
- 2017-11-30 AU AU2017268649A patent/AU2017268649A1/en not_active Abandoned
-
2018
- 2018-07-26 US US16/046,247 patent/US10813921B2/en active Active
- 2018-12-17 US US16/222,305 patent/USRE48608E1/en active Active
- 2018-12-27 JP JP2018245609A patent/JP6837469B2/ja active Active
-
2019
- 2019-01-22 HR HRP20190143TT patent/HRP20190143T1/hr unknown
- 2019-01-24 CY CY20191100100T patent/CY1121386T1/el unknown
- 2019-08-20 AU AU2019219727A patent/AU2019219727B2/en active Active
-
2020
- 2020-10-26 US US17/079,859 patent/US20250082621A9/en active Pending
- 2020-11-17 HR HRP20201827TT patent/HRP20201827T1/hr unknown
- 2020-11-25 CY CY20201101114T patent/CY1123816T1/el unknown
-
2021
- 2021-02-09 JP JP2021019383A patent/JP7277493B2/ja active Active
- 2021-08-20 AU AU2021218172A patent/AU2021218172A1/en not_active Abandoned
-
2023
- 2023-05-08 JP JP2023076515A patent/JP2023109807A/ja not_active Withdrawn
-
2024
- 2024-09-24 AU AU2024219997A patent/AU2024219997A1/en active Pending
-
2025
- 2025-06-11 JP JP2025097940A patent/JP2025148351A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010008835A (es) | Metodo para predecir respuesta al tratamiento farmacologico con chaperona de enfermedades. | |
| MX2008014679A (es) | Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry. | |
| GB2483810B (en) | Methods for correlating clonotypes with diseases in a population | |
| ES2530843T3 (es) | Métodos basados en microARN para el diagnóstico de cáncer de páncreas | |
| NZ602369A (en) | Anti-cxcr1 compositions and methods | |
| WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
| GB2463401B (en) | Characterizing prostate disorders by analysis of microvesicles | |
| MX382244B (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales | |
| WO2011133477A3 (en) | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression | |
| EA036698B9 (ru) | Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif | |
| WO2009085234A3 (en) | Use of micro-rna as a biomarker of immunomodulatory drug activity | |
| NZ595356A (en) | Methods of predicting cancer risk using gene expression in premalignant tissue | |
| MX2009013649A (es) | Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma. | |
| AR088827A1 (es) | Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer | |
| MX2009008736A (es) | Metodos para detectar la enfermedad inflamatoria intestinal. | |
| WO2009025852A3 (en) | Methods of using mirna for detection of in vivo cell death | |
| WO2012078623A3 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| WO2010036960A8 (en) | Methods for treating, diagnosing, and monitoring lupus | |
| NZ596614A (en) | Diagnosis and treatment of alzheimer's disease | |
| EA200801046A1 (ru) | Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro | |
| EP2857522A3 (en) | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy | |
| BRPI1008936B8 (pt) | método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano | |
| WO2009122444A3 (en) | Method for the diagnosis of higher- and lower-grade astrocytoma using biomarkers and diagnostic kit thereof | |
| WO2008099608A1 (ja) | 炎症性腸疾患の診断方法 | |
| WO2009060317A3 (en) | Absorptive matrix methods for the diagnosis and monitoring of disease and assessment of effects of therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |